PPI no better than placebo for chronic cough
ESOMEPRAZOLE has no clinically important advantage over placebo in the treatment of patients with chronic cough, a small study shows.
The proton pump inhibitor (PPI) was used in a randomised, double-blind, placebo-controlled study in the UK involving 50 adult non-smokers with chronic cough and normal spirometry, to see how their cough score improved.
Subjects received either esomeprazole 20 mg twice daily or matched placebo over eight weeks, with no serious adverse events recorded during the study.
Both the placebo and treatment arms improved significantly, with no big differences between them, suggesting a strong placebo effect, the authors said.
They noted a strong placebo effect was highlighted in a previous meta-analysis of anti-acid therapy in chronic cough.
“A role for acid suppression in the treatment of GOR-associated chronic cough remains uncertain,” they concluded.
Associate Professor Geoff